Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | INSR | P06213 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6002823 | 0.81 | MAPT (0.54) | RAB9AMAPTNPC1MEN1KMT2A | |
| SCHEMBL288476 | 0.81 | MAPT (0.57) | RAB9AMAPTNPC1MEN1KMT2A | |
| SCHEMBL27287378 | 0.79 | RAB9A (0.51) | RAB9AMAPTNPC1MEN1KMT2A | |
| SCHEMBL3096386 | 0.79 | MAPT (0.51) | RAB9AMAPTNPC1MEN1KMT2A | |
| SCHEMBL27468350 | 0.79 | RAB9A (0.51) | RAB9AMAPTNPC1MEN1KMT2A | |
| SCHEMBL29954323 | 0.79 | PSMB8 (0.53) | RAB9AMAPTNPC1MEN1KMT2A | |
| SCHEMBL719081 | 0.79 | MAPT (0.56) | RAB9AMAPTNPC1MEN1KMT2A | |
| SCHEMBL19844258 | 0.79 | RAB9A (0.51) | RAB9AMAPTNPC1MEN1KMT2A | |
| SCHEMBL221982 | 0.79 | PSMB8 (0.53) | RAB9AMAPTNPC1MEN1KMT2A | |
| SCHEMBL28032600 | 0.79 | RAB9A (0.51) | RAB9AMAPTNPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116354996-A | Benzothiazole vinyl-containing BODIPY dimer fluorescent probe DHB-BODIPY and preparation method and application thereof | 淮阴工学院 | 2023-06-30 | — | — | CN | claimed |
| US-20150202185-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | TAIJI BIOMEDICAL, INC. | 2015-07-23 | — | — | US | claimed |
| US-20130012539-A1 | Compositions and Methods for Treating Lysosomal Disorders | THE HOSPITAL FOR SICK CHILDREN (CA) | 2013-01-10 | — | — | US | claimed |
| EP-2211856-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | The Hospital For Sick Children (CA) | 2010-08-04 | — | — | EP | claimed |
| EP-2082740-A2 | Use of imidazole derivatives as MDR modulators | Taiji Biomedical, Inc. (US) | 2009-07-29 | — | — | EP | claimed |
| US-20090163500-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-06-25 | — | — | US | claimed |
| WO-2009073564-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-06-11 | — | — | WO | claimed |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TAIJI BIOMEDICAL, INC. (US) | 2007-08-30 | — | — | US | claimed |
| EP-0999835-A4 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORP (US) | 2004-08-25 | — | — | EP | claimed |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TAIJI BIOMEDICAL, INC. | 2002-10-10 | — | — | US | claimed |
| EP-0999835-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | Ontogen Corporation (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999002155-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORPORATION (US) | 1999-01-21 | — | — | WO | claimed |
| CN-112794857-B | Fluorescent probe for ferrous ion detection and preparation and application thereof | 湖南超亟检测技术有限责任公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116354996-A | Benzothiazole vinyl-containing BODIPY dimer fluorescent probe DHB-BODIPY and preparation method and application thereof | 淮阴工学院 | 2023-06-30 | — | — | CN | disclosed |
| CN-108699035-B | Novel compounds | 特殊治疗有限公司 | 2021-10-15 | — | — | CN | disclosed |
| US-20150202185-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | TAIJI BIOMEDICAL, INC. | 2015-07-23 | — | — | US | disclosed |
| EP-0944594-A1 | INHIBITORS OF THE ENZYMATIC ACTIVITY OF PSA | ELI LILLY AND COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999002155-A1 | IMIDAZOLE DERIVATIVES AS MDR MODULATORS | ONTOGEN CORPORATION (US) | 1999-01-21 | — | — | WO | disclosed |
| US-5840721-A | INCREASE SENSITIVITY OF MULTIDRUG RESISTANT TUMOR CELLS TO ANTICANCER AGENTS | ONTOGEN CORPORATION (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998025895-A1 | INHIBITORS OF THE ENZYMATIC ACTIVITY OF PSA | ELI LILLY AND COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163500-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | GAA, GBA1, LIPA | RAB9A 252/4885MAPT 691/4885NPC1 15/4885 |
| US-20130012539-A1 | Compositions and Methods for Treating Lysosomal Disorders | GAA, GBA1, LIPA | RAB9A 252/4885MAPT 691/4885NPC1 15/4885 |
| US-20070203215-A1 | Methods & Compositions For Enhancing Pharmaceutical Treatments | TUBB3, TUBB1, TUBB2A | RAB9A 1628/4885MAPT 26/4885NPC1 45/4885 |
| US-20020147197-A1 | Methods and compositions for enhancing pharmaceutical treatments | TUBB3, TUBB1, TUBB2A | RAB9A 2063/4885MAPT 39/4885NPC1 62/4885 |
| US-20150202185-A1 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDERS | GAA, GBA1, LIPA | RAB9A 252/4885MAPT 691/4885NPC1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.